Compare · head to head
Nov vs Verrica Pharmaceuticals
Verrica Pharmaceuticals ranks higher overall — 360 rank 55 vs 39.
Verrica Pharmaceuticals leads on Quality (52 vs 46) and Sentiment (60 vs 48). Nov leads on Growth (51 vs 38). The two are close on Safety.
Ranks as of 2026-06-12 · 1–100 vs true peers. Higher is better.
| Compare | ||
|---|---|---|
| Profile | ||
| Country | USA | USA |
| Sector | Energy & Oil | Health Care |
| Industry | Energy Equipment & Services | Pharmaceuticals |
| Size | X-Large | Small |
| ISIN | US62955J1034 | US92511W2070 |
| Last update | 2026-04-02 | 2026-04-02 |
| History | ||
| 360 (V1) since 2023 | ||
| Ranks | ||
| 360 | 39 | 55 |
| Value | 40 | NR |
| Quality | 46 | 52 |
| Growth | 51 | 38 |
| Safety | 52 | 54 |
| Sentiment | 48 | 60 |
| Quality details | ||
| Profitability | 28 | 53 |
| Cash Truth | 64 | NR |
Nov vs CES Energy SolutionsNov vs LENSARNov vs Republic Airways HoldingsNov vs Core LaboratoriesAdd a third stock →
Full analyses: Nov · Verrica Pharmaceuticals
Make Sense of the Ranks
Every rank runs 1–100 against true peers. Higher is always better.
360° View
1 · Watch OutGood· 100
Value
1 · ExpensiveGood Value· 100
Quality
1 · Weak FundamentalsHigh Quality· 100
Growth
1 · Tough TimesHigh Growth· 100
Safety
1 · High LeverageWell-Financed· 100
Sentiment
1 · SkepticismPositive· 100